EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

ICOSLG Is Associated with Anti-PD-1 and Concomitant Antihistamine Treatment Response in Advanced Melanoma

Domenico Mallardo iD, Mario Fordellone iD, Margaret Ottaviano iD, Giuseppina Marano, Maria Grazia Vitale iD, Mario Mallardo, Mariagrazia Capasso, Teresa De Cristofaro, Mariaelena Capone iD, Teresa Meinardi iD, Miriam Paone iD, Patrizia Sabatelli und 8 weitere

International Journal of Molecular Sciences · 2024

DOI: 10.3390/ijms252212439 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2024. Verfasst von Domenico Mallardo und 19 weiteren Autor:innen. Beteiligte Einrichtung: Melanoma, Cancer Immunotherapy and Development Therapeutics Unit, Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale", Via Mariano Semmola, 53, 8…. Hauptthemen laut MEDLINE: Melanoma, Immune Checkpoint Inhibitors. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: This study received a grant from the Italian Ministry of Health (IT-MOH), Italian Ministry of Health (IT-MOH).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

We previously demonstrated that patients with metastatic unresectable stage IIIb–IV melanoma receiving cetirizine (a second-generation H1 antagonist antihistamine) premedication with immunotherapy had better outcomes than those not receiving cetirizine. In this retrospective study, we searched for a gene signature potentially predictive of the response to the addition of cetirizine to checkpoint inhibition (nivolumab or pembrolizumab with or without previous ipilimumab). Transcriptomic analysis showed that inducible T cell costimulator ligand (ICOSLG) expression directly correlated with the disease control rate (DCR) when detected with a loading value > 0.3. A multivariable logistic regression model showed a positive association between the DCR and ICOSLG expression for progression-free survival and overall survival. ICOSLG expression was associated with CD64, a specific marker of M1 macrophages, at baseline in the patient samples who received cetirizine concomitantly with checkpoint inhibitors, but this association was not present in subjects who had not received cetirizine. In conclusion, our results show that the clinical advantage of concomitant treatment with cetirizine during checkpoint inhibition in patients with malignant melanoma is associated with high ICOSLG expression, which could predict the response to immune checkpoint inhibitor blockade.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MelanomaImmune Checkpoint InhibitorsHumansMaleFemaleMiddle AgedAgedRetrospective StudiesCetirizineAntibodies, Monoclonal, HumanizedNivolumabProgrammed Cell Death 1 ReceptorAdultTreatment OutcomeHistamine Antagonists

Stichwörter der Autor:innen

biomarkercetirizinecheckpoint inhibitioncutaneous melanoma

Substanzen

Immune Checkpoint InhibitorsCetirizineAntibodies, Monoclonal, HumanizedNivolumabProgrammed Cell Death 1 ReceptorpembrolizumabHistamine Antagonists

Autor:innen und Institutionen

  • Melanoma, Cancer Immunotherapy and Development Therapeutics Unit, Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale", Via Mariano Semmola, 53, 80131 Naples, Italy.
  • Medical Statistics Unit, Universitiy of Campania "Luigi Vanvitelli", 81100 Naples, Italy.
  • Department of Clinical Medicine and Surgery, University of Naples Federico II, 80138 Naples, Italy.
  • ESSA Pharma, South San Francisco, CA 94080, USA.
  • Division of Laboratory Medicine, Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale", 80131 Naples, Italy.
  • Division of Surgery of Melanoma and Skin Cancer, Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale", 80131 Naples, Italy.

ORCID-Profile: Domenico Mallardo, Mario Fordellone, Margaret Ottaviano, Maria Grazia Vitale, Mariaelena Capone, Teresa Meinardi, Miriam Paone, Rosaria De Filippi, Ernesta Cavalcanti, Alfredo Budillon

Förderung

  • This study received a grant from the Italian Ministry of Health (IT-MOH)
  • Italian Ministry of Health (IT-MOH)

Zitieren

APA

Mallardo, D., Fordellone, M., Ottaviano, M., Marano, G., Vitale, M. G., Mallardo, M., Capasso, M., De Cristofaro, T., Capone, M., Meinardi, T., Paone, M., Sabatelli, P., De Filippi, R., Cesano, A., Cavalcanti, E., Caracò, C., Warren, S., Budillon, A., Simeone, E., & Ascierto, P. A. (2024). ICOSLG Is Associated with Anti-PD-1 and Concomitant Antihistamine Treatment Response in Advanced Melanoma. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms252212439

Vancouver

Mallardo D, Fordellone M, Ottaviano M, Marano G, Vitale MG, Mallardo M, et al. ICOSLG Is Associated with Anti-PD-1 and Concomitant Antihistamine Treatment Response in Advanced Melanoma. International Journal of Molecular Sciences. 2024. doi:10.3390/ijms252212439

BibTeX
@article{Mallardo2024,
  author = {Mallardo, Domenico and Fordellone, Mario and Ottaviano, Margaret and Marano, Giuseppina and Vitale, Maria Grazia and Mallardo, Mario and Capasso, Mariagrazia and De Cristofaro, Teresa and Capone, Mariaelena and Meinardi, Teresa and Paone, Miriam and Sabatelli, Patrizia and De Filippi, Rosaria and Cesano, Alessandra and Cavalcanti, Ernesta and Caracò, Corrado and Warren, Sarah and Budillon, Alfredo and Simeone, Ester and Ascierto, Paolo Antonio},
  title = {ICOSLG Is Associated with Anti-PD-1 and Concomitant Antihistamine Treatment Response in Advanced Melanoma},
  journal = {International Journal of Molecular Sciences},
  year = {2024},
  doi = {10.3390/ijms252212439}
}
Kostenlos starten →